Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
Can J Neurol Sci
; 45(6): 652-659, 2018 11.
Article
en En
| MEDLINE
| ID: mdl-30430962
ABSTRACT
BACKGROUND:
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease resulting in muscle weakness, dysarthria and dysphagia, and ultimately respiratory failure leading to death. Half of the ALS patients survive less than 3 years, and 80% of the patients survive less than 5 years. Riluzole is the only approved medication in Canada with randomized controlled clinical trial evidence to slow the progression of ALS, albeit only to a modest degree. The Canadian Neuromuscular Disease Registry (CNDR) collects data on over 140 different neuromuscular diseases including ALS across ten academic institutions and 28 clinics including ten multidisciplinary ALS clinics.METHODS:
In this study, CNDR registry data were analyzed to examine potential differences in ALS care among provinces in time to diagnosis, riluzole and feeding tube use.RESULTS:
Significant differences were found among provinces, in time to diagnosis from symptom onset, in the use of riluzole and in feeding tube use.CONCLUSIONS:
Future investigations should be undertaken to identify factors contributing to such differences, and to propose potential interventions to address the provincial differences reported.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Antagonistas de Aminoácidos Excitadores
/
Riluzol
/
Esclerosis Amiotrófica Lateral
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Can J Neurol Sci
Año:
2018
Tipo del documento:
Article
País de afiliación:
Canadá